Personalized mRNA vaccine keeps pancreatic cancer at bay six years after treatment
Personalized mRNA cancer vaccine shows remarkable results in a small but significant trial for pancreatic cancer, one of medicine’s most stubborn killers. Six years after treatment, seven of eight patients who mounted an immune response remain alive — extraordinary for a disease with a five-year survival rate below 13%. The custom-built vaccine targets genetic mutations unique to each patient’s tumor, training the immune system to eliminate remaining cancer cells after surgery. New findings suggest the immune response may be self-sustaining, with helper T cells replenishing the killer T cells that attack cancer. A larger Phase 2 trial is now underway.









